In this fast-moving industry, BioCT keeps policy makers and influencers abreast of the latest developments and changing needs of the bioscience community.
Our mission is to provide education and advocacy for Connecticut’s bioscience and life science communities at the policy level and ensure synergy of action and alignment of state and federal initiatives that have a significant impact on our members.
The Government Affairs Committee is comprised of BioCT board members, industry executives and business advisors including the government relations firm of Rome, Smith & Lutz, which has deep expertise in matters impacting our industry.
President & CEO,
Senior Manager, State Government Affairs,
Bristol Myers Squibb
Kathy Andrews Bilotas
Director of State Government Affairs,
Partner, Tax Services,
Fiondella, Milone & LaSaracina
Chief Financial Officer
Director, State Government Affairs – East,
State Government Affairs, Regional Director,
Director, US Government Relations/Corporate Affairs,
Associate Vice President for Federal Relations,
Director, State Government Relations,
Senior Director, Government Relations,
University of Connecticut
Director, State Government Affairs and Public Policy,
Rome, Smith & Lutz
Regional Director, State Government Affairs,
Director, Alliance Development
Rome Smith & Lutz
State Government Affairs Manager, East Coast,
July 14, 2021
May 12, 2021
We believe the legislation, though well-intentioned, is flawed on at least five fronts.
May 8, 2021
In the recent letter to President Biden from BIO’s President & CEO, Dr. Michelle McMurry-Heath, BIO suggests the establishment of a COVID Global Strategy for Harnessing Access Reaching Everyone (SHARE) Program, to be implemented immediately.
April 20, 2021
On behalf of BIO, BioCT and our Board of Directors, as shown, we are writing in support of SB 1099, An Act Authorizing Bonds of the State for a Research Faculty Recruitment and Hiring Program by the University of Connecticut To Encourage the Creation of New Business Venture.
April 20, 2021
On behalf of BIO, BioCT and our Board of Directors, as shown, we are writing in support of SB 1094, An Act Authorizing Bonds of the State for CTNext and the Innovation Place Program.
BioCT’s advocacy wins at the state level include:
Federal advocacy focuses on the continuing robustness of these agencies:
President & CEO